figshare
Browse

Data availability.xlsx

Download (15.95 kB)
Version 2 2023-05-29, 03:00
Version 1 2023-05-03, 05:35
dataset
posted on 2023-05-29, 03:00 authored by Tenri Esa BuduTenri Esa Budu

  

· Studies on Covid-19 need to continue to be developed for prevention and management both now and in the future.

· IL-6 and NLR could be a biomarker of the severity of COVID-19 disease

· The differences in serum levels of the pro-inflammatory cytokine IL-6 and the imbalance of inflammatory cells with NLR can be part of the handling procedure for COVID-19.

· The result cut-off> 6.99 pg/mL and Neutrophil Lymphocyte Ratio (NLR) > 4.18 is the potential to be included in laboratory parameters for patient management of COVID-19.

Funding

Tenri Esa

Budu

Budi Mulyono

Gita Vita Soraya

Andi Nilawati Usman

Umi Solekhah Intansari

History

Usage metrics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC